Therapy with interferon-β modulates endogenous catecholamines in lymphocytes of patients with multiple sclerosis

Mauro Zaffaroni, Franca Marino, Raffaella Bombelli, Emanuela Rasini, Marta Monti, Marco Ferrari, Angelo Ghezzi, Giancarlo Comi, Sergio Lecchini, Marco Cosentino

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Objective: To investigate the endogenous dopaminergic/adrenergic system of lymphocytes in multiple sclerosis (MS) patients during treatment with interferon (IFN)-β. Methods: Patients with relapsing-remitting MS undergoing IFN-β treatment were prospectively studied during the first year of treatment. Circulating lymphocytes were obtained at baseline and after 1, 3, 6 and 12 months of treatment and assayed for catecholamine (CA) production and mRNA expression of tyrosine hydroxylase (TH, the rate-limiting enzyme in the synthesis of CA), β 2-adrenoceptors (AR) and D2, D3 and D5 dopaminergic receptors (DR). Results: In cells from patients treated with IFN-β for 12 months the production of CA hugely increased and was less sensitive to IFN-γ-induced inhibition. Expression of mRNA for TH, β 2-AR and DRD5 was already enhanced after 1 month and further increased up to 6-12 months of treatment. On the contrary, DRD2 mRNA progressively decreased and DRD3 mRNA did not significantly change over the whole study period. Conclusions: In MS patients IFN-β treatment enhances the ability of lymphocytes to produce CA, and induces extensive modifications of both β 2-AR and DR-operated pathways. The clinical relevance of these effects deserves consideration.

Original languageEnglish
Pages (from-to)315-321
Number of pages7
JournalExperimental Neurology
Volume214
Issue number2
DOIs
Publication statusPublished - Dec 2008

Fingerprint

Interferons
Multiple Sclerosis
Catecholamines
Lymphocytes
Adrenergic Receptors
Messenger RNA
Therapeutics
Relapsing-Remitting Multiple Sclerosis
Tyrosine 3-Monooxygenase
Adrenergic Agents
Enzymes

Keywords

  • Catecholamine receptors
  • Catecholamines
  • Interferon beta
  • Lymphocytes
  • Multiple sclerosis

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience

Cite this

Zaffaroni, M., Marino, F., Bombelli, R., Rasini, E., Monti, M., Ferrari, M., ... Cosentino, M. (2008). Therapy with interferon-β modulates endogenous catecholamines in lymphocytes of patients with multiple sclerosis. Experimental Neurology, 214(2), 315-321. https://doi.org/10.1016/j.expneurol.2008.08.015

Therapy with interferon-β modulates endogenous catecholamines in lymphocytes of patients with multiple sclerosis. / Zaffaroni, Mauro; Marino, Franca; Bombelli, Raffaella; Rasini, Emanuela; Monti, Marta; Ferrari, Marco; Ghezzi, Angelo; Comi, Giancarlo; Lecchini, Sergio; Cosentino, Marco.

In: Experimental Neurology, Vol. 214, No. 2, 12.2008, p. 315-321.

Research output: Contribution to journalArticle

Zaffaroni, M, Marino, F, Bombelli, R, Rasini, E, Monti, M, Ferrari, M, Ghezzi, A, Comi, G, Lecchini, S & Cosentino, M 2008, 'Therapy with interferon-β modulates endogenous catecholamines in lymphocytes of patients with multiple sclerosis', Experimental Neurology, vol. 214, no. 2, pp. 315-321. https://doi.org/10.1016/j.expneurol.2008.08.015
Zaffaroni, Mauro ; Marino, Franca ; Bombelli, Raffaella ; Rasini, Emanuela ; Monti, Marta ; Ferrari, Marco ; Ghezzi, Angelo ; Comi, Giancarlo ; Lecchini, Sergio ; Cosentino, Marco. / Therapy with interferon-β modulates endogenous catecholamines in lymphocytes of patients with multiple sclerosis. In: Experimental Neurology. 2008 ; Vol. 214, No. 2. pp. 315-321.
@article{a40ad8af423d40cea4fb5b47a0484cbe,
title = "Therapy with interferon-β modulates endogenous catecholamines in lymphocytes of patients with multiple sclerosis",
abstract = "Objective: To investigate the endogenous dopaminergic/adrenergic system of lymphocytes in multiple sclerosis (MS) patients during treatment with interferon (IFN)-β. Methods: Patients with relapsing-remitting MS undergoing IFN-β treatment were prospectively studied during the first year of treatment. Circulating lymphocytes were obtained at baseline and after 1, 3, 6 and 12 months of treatment and assayed for catecholamine (CA) production and mRNA expression of tyrosine hydroxylase (TH, the rate-limiting enzyme in the synthesis of CA), β 2-adrenoceptors (AR) and D2, D3 and D5 dopaminergic receptors (DR). Results: In cells from patients treated with IFN-β for 12 months the production of CA hugely increased and was less sensitive to IFN-γ-induced inhibition. Expression of mRNA for TH, β 2-AR and DRD5 was already enhanced after 1 month and further increased up to 6-12 months of treatment. On the contrary, DRD2 mRNA progressively decreased and DRD3 mRNA did not significantly change over the whole study period. Conclusions: In MS patients IFN-β treatment enhances the ability of lymphocytes to produce CA, and induces extensive modifications of both β 2-AR and DR-operated pathways. The clinical relevance of these effects deserves consideration.",
keywords = "Catecholamine receptors, Catecholamines, Interferon beta, Lymphocytes, Multiple sclerosis",
author = "Mauro Zaffaroni and Franca Marino and Raffaella Bombelli and Emanuela Rasini and Marta Monti and Marco Ferrari and Angelo Ghezzi and Giancarlo Comi and Sergio Lecchini and Marco Cosentino",
year = "2008",
month = "12",
doi = "10.1016/j.expneurol.2008.08.015",
language = "English",
volume = "214",
pages = "315--321",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Therapy with interferon-β modulates endogenous catecholamines in lymphocytes of patients with multiple sclerosis

AU - Zaffaroni, Mauro

AU - Marino, Franca

AU - Bombelli, Raffaella

AU - Rasini, Emanuela

AU - Monti, Marta

AU - Ferrari, Marco

AU - Ghezzi, Angelo

AU - Comi, Giancarlo

AU - Lecchini, Sergio

AU - Cosentino, Marco

PY - 2008/12

Y1 - 2008/12

N2 - Objective: To investigate the endogenous dopaminergic/adrenergic system of lymphocytes in multiple sclerosis (MS) patients during treatment with interferon (IFN)-β. Methods: Patients with relapsing-remitting MS undergoing IFN-β treatment were prospectively studied during the first year of treatment. Circulating lymphocytes were obtained at baseline and after 1, 3, 6 and 12 months of treatment and assayed for catecholamine (CA) production and mRNA expression of tyrosine hydroxylase (TH, the rate-limiting enzyme in the synthesis of CA), β 2-adrenoceptors (AR) and D2, D3 and D5 dopaminergic receptors (DR). Results: In cells from patients treated with IFN-β for 12 months the production of CA hugely increased and was less sensitive to IFN-γ-induced inhibition. Expression of mRNA for TH, β 2-AR and DRD5 was already enhanced after 1 month and further increased up to 6-12 months of treatment. On the contrary, DRD2 mRNA progressively decreased and DRD3 mRNA did not significantly change over the whole study period. Conclusions: In MS patients IFN-β treatment enhances the ability of lymphocytes to produce CA, and induces extensive modifications of both β 2-AR and DR-operated pathways. The clinical relevance of these effects deserves consideration.

AB - Objective: To investigate the endogenous dopaminergic/adrenergic system of lymphocytes in multiple sclerosis (MS) patients during treatment with interferon (IFN)-β. Methods: Patients with relapsing-remitting MS undergoing IFN-β treatment were prospectively studied during the first year of treatment. Circulating lymphocytes were obtained at baseline and after 1, 3, 6 and 12 months of treatment and assayed for catecholamine (CA) production and mRNA expression of tyrosine hydroxylase (TH, the rate-limiting enzyme in the synthesis of CA), β 2-adrenoceptors (AR) and D2, D3 and D5 dopaminergic receptors (DR). Results: In cells from patients treated with IFN-β for 12 months the production of CA hugely increased and was less sensitive to IFN-γ-induced inhibition. Expression of mRNA for TH, β 2-AR and DRD5 was already enhanced after 1 month and further increased up to 6-12 months of treatment. On the contrary, DRD2 mRNA progressively decreased and DRD3 mRNA did not significantly change over the whole study period. Conclusions: In MS patients IFN-β treatment enhances the ability of lymphocytes to produce CA, and induces extensive modifications of both β 2-AR and DR-operated pathways. The clinical relevance of these effects deserves consideration.

KW - Catecholamine receptors

KW - Catecholamines

KW - Interferon beta

KW - Lymphocytes

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=56349094317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56349094317&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2008.08.015

DO - 10.1016/j.expneurol.2008.08.015

M3 - Article

VL - 214

SP - 315

EP - 321

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

IS - 2

ER -